PHIO PHARMACEUTICALS CORP.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-8.7M | $-7.2M | $-10.8M | $-11.5M | $-13.3M | $-8.8M | $-8.9M | $-7.4M |
| Depreciation & Amortization | $3.0K | $2.0K | $56.0K | $71.0K | $75.0K | $72.0K | $67.0K | $81.0K |
| Depreciation | — | $2.0K | $56.0K | $71.0K | $75.0K | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $481.0K | $147.0K | $303.0K | $414.0K | $480.0K | $136.0K | $300.0K | $282.0K |
| Net Cash from Operating Activities | $-8.0M | $-7.1M | $-10.7M | $-12.1M | $-11.9M | $-8.8M | $-8.6M | $-7.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $12.0K | $1.0K | $5.0K | $121.0K | $51.0K | $19.0K | $72.0K | $5.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-12.0K | $8.0K | $-5.0K | $-121.0K | $-51.0K | $-19.0K | $-72.0K | $-5.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $23.6M | $4.0M | $7.4M | $-26.0K | $21.7M | $16.1M | $772.0K | $18.8M |
| Net Change in Cash | $15.6M | $-3.1M | — | — | — | — | — | $11.3M |
| Free Cash Flow | $-8.0M | $-7.1M | $-10.8M | $-12.3M | $-11.9M | $-8.8M | $-8.7M | $-7.5M |
A great business at a fair price is superior to a fair business at a great price.